{
  "id": "54519e0138910b9a",
  "title": "A new CRISPR startup is betting regulators will ease up on gene-editing",
  "description": "Here at MIT Technology Review we\u2019ve been writing about the gene-editing technology CRISPR since 2013, calling it the biggest biotech breakthrough of the century. Yet so far, there\u2019s been only one gene-editing drug approved. It\u2019s been used commercially on only about 40 patients, all with sickle-cell disease. It\u2019s becoming clear that the impact of CRISPR&#8230;",
  "content": "Here at MIT Technology Review we\u2019ve been writing about the gene-editing technology CRISPR since 2013, calling it the biggest biotech breakthrough of the century. Yet so far, there\u2019s been only one gene-editing drug approved. It\u2019s been used commercially on only about 40 patients, all with sickle-cell disease. It\u2019s becoming clear that the impact of CRISPR&#8230;",
  "source": "MIT Technology Review",
  "source_url": "https://www.technologyreview.com/2026/01/09/1130945/crispr-startup-aurora-betting-regulation-pku/",
  "published_at": "2026-01-09T11:00:00+00:00",
  "fetched_at": "2026-01-10T00:22:56.872596+00:00",
  "category": "ai_machine_intelligence",
  "subcategory": null,
  "keywords": [
    "crispr",
    "drug"
  ],
  "location": null,
  "raw_data": {
    "title": "A new CRISPR startup is betting regulators will ease up on gene-editing",
    "description": "Here at MIT Technology Review we\u2019ve been writing about the gene-editing technology CRISPR since 2013, calling it the biggest biotech breakthrough of the century. Yet so far, there\u2019s been only one gene-editing drug approved. It\u2019s been used commercially on only about 40 patients, all with sickle-cell disease. It\u2019s becoming clear that the impact of CRISPR&#8230;",
    "url": "https://www.technologyreview.com/2026/01/09/1130945/crispr-startup-aurora-betting-regulation-pku/",
    "published": "2026-01-09T11:00:00+00:00",
    "source": "MIT Technology Review"
  }
}